Brand Name

Vyzulta

Generic Name
Latanoprostene Bunod
View Brand Information
FDA approval date: November 02, 2017
Form: Solution

What is Vyzulta (Latanoprostene Bunod)?

VYZULTA ®

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma.
The effect of latanoprostene bunod on retinal vessel density in patients with primary open-angle glaucoma.
Journal: European journal of ophthalmology
Published: November 14, 2025
Angina Pectoris Following Latanoprostene Bunod 0.024% Administration: A Case Report.
Angina Pectoris Following Latanoprostene Bunod 0.024% Administration: A Case Report.
Journal: Cureus
Published: November 10, 2025
Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study.
Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Published: September 16, 2025
View All Latest Advances